Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure

[1]  Haidi Chen,et al.  Constitutively active BRS3 is a genuinely orphan GPCR in placental mammals , 2019, PLoS biology.

[2]  P. Phansuwan-Pujito,et al.  Neuroprotective effects of melatonin on amphetamine‐induced dopaminergic fiber degeneration in the hippocampus of postnatal rats , 2018, Journal of pineal research.

[3]  B. Giros,et al.  Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions , 2018, Neuropsychopharmacology.

[4]  M. Dubocovich,et al.  Update on melatonin receptors: IUPHAR Review 20 , 2016, British journal of pharmacology.

[5]  I. Jurisica,et al.  Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons , 2016, Journal of pineal research.

[6]  E. Cecon,et al.  Amyloid β peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  H. Sitte,et al.  Amphetamines, new psychoactive drugs and the monoamine transporter cycle , 2014, Trends in pharmacological sciences.

[8]  H. Sitte,et al.  Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism , 2014, Neuropharmacology.

[9]  S. Berretta,et al.  Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia. , 2014, Schizophrenia bulletin.

[10]  E. Cecon,et al.  MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. , 2014, Journal of medicinal chemistry.

[11]  K. Ishii,et al.  Comparison of dopamine transporter decline in a patient with Parkinson's disease and normal aging effect , 2014, Journal of the Neurological Sciences.

[12]  G. Bishop,et al.  Behavior of knock-in mice with a cocaine-insensitive dopamine transporter after virogenetic restoration of cocaine sensitivity in the striatum , 2014, Neuropharmacology.

[13]  E. Puffenberger,et al.  Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood , 2014, Brain : a journal of neurology.

[14]  V. Wong,et al.  The identification of novel proteins that interact with the GLP-1 receptor and restrain its activity. , 2013, Molecular endocrinology.

[15]  S. Angers,et al.  A Novel Assay for Measurement of Membrane‐Protein Surface Expression using a β‐lactamase Reporter , 2013, Traffic.

[16]  R. Jockers,et al.  Minireview: Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. , 2013, Molecular endocrinology.

[17]  S. Ohdo,et al.  Molecular Mechanism Regulating 24-Hour Rhythm of Dopamine D3 Receptor Expression in Mouse Ventral Striatum , 2013, Molecular Pharmacology.

[18]  Kun-Ju Lin,et al.  The interaction between dopamine transporter function, gender differences, and possible laterality in depression , 2013, Psychiatry Research: Neuroimaging.

[19]  G. Hanson,et al.  Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization , 2012, Journal of neurochemistry.

[20]  O. Nosjean,et al.  Description of the constitutive activity of cloned human melatonin receptors hMT1 and hMT2 and discovery of inverse agonists , 2012, Journal of pineal research.

[21]  Jordi Ortiz,et al.  Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland , 2012, PLoS biology.

[22]  S. Amir,et al.  Endogenous Dopamine Regulates the Rhythm of Expression of the Clock Protein PER2 in the Rat Dorsal Striatum via Daily Activation of D2 Dopamine Receptors , 2010, The Journal of Neuroscience.

[23]  M. Dubocovich,et al.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors , 2010, Pharmacological Reviews.

[24]  Victoria Wong,et al.  Detecting interactions with membrane proteins using a membrane two-hybrid assay in yeast , 2010, Nature Protocols.

[25]  Ulrik Gether,et al.  Regulation of dopamine transporter function by protein‐protein interactions: new discoveries and methodological challenges , 2010, Journal of neurochemistry.

[26]  D. Mash,et al.  Melatonin MT1 and MT2 receptor expression in Parkinson's disease. , 2010, Medical science monitor : international medical journal of experimental and clinical research.

[27]  A. Scates,et al.  Melatonin Treatment for Insomnia in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder , 2010, The Annals of pharmacotherapy.

[28]  J. Lanciego,et al.  Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease , 2009, Neurobiology of Disease.

[29]  H. Sitte,et al.  Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3 , 2009, The Journal of Neuroscience.

[30]  J. Javitch,et al.  Syntaxin 1A Interaction with the Dopamine Transporter Promotes Amphetamine-Induced Dopamine Efflux , 2008, Molecular Pharmacology.

[31]  M. Migaud,et al.  The PDZ Protein Mupp1 Promotes Gi Coupling and Signaling of the Mt1 Melatonin Receptor* , 2008, Journal of Biological Chemistry.

[32]  M. Reith,et al.  Substrates dissociate dopamine transporter oligomers , 2008, Journal of neurochemistry.

[33]  J. Chuang,et al.  Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats , 2008, Journal of pineal research.

[34]  J. Mallet,et al.  Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity , 2007, Proceedings of the National Academy of Sciences.

[35]  G. Tocchini-Valentini,et al.  GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs , 2007, Proceedings of the National Academy of Sciences.

[36]  J. Javitch,et al.  D2 Receptors Regulate Dopamine Transporter Function via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent and Phosphoinositide 3 Kinase-Independent Mechanism , 2007, Molecular Pharmacology.

[37]  A. Björklund,et al.  Fifty years of dopamine research , 2007, Trends in Neurosciences.

[38]  Fang Liu,et al.  Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor , 2007, The EMBO journal.

[39]  A. Sorkin,et al.  Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. , 2006, Molecular biology of the cell.

[40]  R. Ravid,et al.  Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. , 2006, European journal of histochemistry : EJH.

[41]  G. Torres,et al.  The dopamine transporter proteome , 2006, Journal of neurochemistry.

[42]  Christine C. Wu,et al.  Enhanced Ubiquitylation and Accelerated Degradation of the Dopamine Transporter Mediated by Protein Kinase C* , 2005, Journal of Biological Chemistry.

[43]  Yogesh K. Dwivedi,et al.  The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. , 2005, Brain research. Molecular brain research.

[44]  H. Manev,et al.  Diurnal rhythms in quinpirole-induced locomotor behaviors and striatal D2/D3 receptor levels in mice , 2005, Pharmacology Biochemistry and Behavior.

[45]  Jian Feng,et al.  Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter* , 2004, Journal of Biological Chemistry.

[46]  P. Delagrange,et al.  Preferential Formation of MT1/MT2 Melatonin Receptor Heterodimers with Distinct Ligand Interaction Properties Compared with MT2 Homodimers , 2004, Molecular Pharmacology.

[47]  J. Javitch,et al.  N-Terminal Phosphorylation of the Dopamine Transporter Is Required for Amphetamine-Induced Efflux , 2004, PLoS biology.

[48]  E. Galperin,et al.  Oligomerization of Dopamine Transporters Visualized in Living Cells by Fluorescence Resonance Energy Transfer Microscopy* , 2003, Journal of Biological Chemistry.

[49]  R. Jockers,et al.  Activation of the Leptin Receptor by a Ligand-induced Conformational Change of Constitutive Receptor Dimers* , 2003, Journal of Biological Chemistry.

[50]  G. Uhl,et al.  Phosphatidylinositol 3-Kinase, Protein Kinase C, and MEK1/2 Kinase Regulation of Dopamine Transporters (DAT) Require N-terminal DAT Phosphoacceptor Sites* , 2003, Journal of Biological Chemistry.

[51]  Jean-François Mercier,et al.  Quantitative Assessment of β1- and β2-Adrenergic Receptor Homo- and Heterodimerization by Bioluminescence Resonance Energy Transfer* , 2002, The Journal of Biological Chemistry.

[52]  D. Abramovich,et al.  Melatonin receptors in human fetal brain: 2‐[125I]iodomelatonin binding and MT1 gene expression , 2002, Journal of pineal research.

[53]  P. Pévet,et al.  MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei , 2002, Brain Research.

[54]  Merja Haaparanta,et al.  Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.

[55]  K. Frey,et al.  Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. , 2000, European journal of pharmacology.

[56]  Darin D Dougherty,et al.  Dopamine transporter density in patients with attention deficit hyperactivity disorder , 1999, The Lancet.

[57]  A. Strosberg,et al.  Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. , 1999, Molecular endocrinology.

[58]  A. Levey,et al.  Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.

[59]  T. Flatmark,et al.  Generation of Reactive Oxygen Species by Tyrosine Hydroxylase: A Possible Contribution to the Degeneration of Dopaminergic Neurons? , 1997, Journal of neurochemistry.

[60]  G. Uhl,et al.  Phorbol Esters Increase Dopamine Transporter Phosphorylation and Decrease Transport Vmax , 1997, Journal of neurochemistry.

[61]  Francisco Vives,et al.  Melatonin‐dopamine interaction in the striatal projection area of sensorimotor cortex in the rat , 1996, Neuroreport.

[62]  R. Elde,et al.  Dopamine transporter mRNA in neurons of the rat hypothalamus. , 1993, Neuroendocrinology.

[63]  M. Caron,et al.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.

[64]  N. Zisapel,et al.  Inhibition of dopamine release by melatonin: regional distribution in the rat brain , 1982, Brain Research.

[65]  R. D. Gietz,et al.  Yeast transformation by the LiAc/SS Carrier DNA/PEG method. , 2006, Methods in molecular biology.

[66]  A. Erbengi,et al.  Behavioural assessment of pinealectomy and foetal pineal gland transplantation in rats: Part II , 2005, Acta Neurochirurgica.

[67]  M. Maj,et al.  Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. , 1997, Neuropsychobiology.